Literature DB >> 23542168

The development of metabolic risk factors after the initiation of the second line anti- retroviral therapy.

Apoorva Mittal1, Basavaprabhu Achappa, Deepak Madi, Mukta N Chowta, John T Ramapuram, Satish Rao, B Unnikrishnan, Soundarya Mahalingam.   

Abstract

BACKGROUND AND
OBJECTIVE: A Highly Active Anti-Retroviral Therapy (HAART) is accompanied with several metabolic effects like adipose redistribution and insulin resistance. In this study, we evaluated the association between a HAART and lipodystrophy.
METHODS: A cross sectional study, whose subjects were Human Immunodeficiency Virus (HIV) infected patients, was conducted at a tertiary care hospital in south India. Among these, 27 were on protease inhibitors for at-least 6 months and 13 were drug naive patients. The assessments of lipodystrophy, fasting blood sugar and the fasting lipid profile were done and these parameters were compared in the two groups.
RESULTS: The analysis of the data which was collected, showed an elevation in the total cholesterol levels in the individuals who were on the protease inhibitors versus the drug naive patients. There was a significant elevation in the Low Density Lipoprotein (LDL) cholesterol levels and a decrease in High Density Lipoprotein (HDL) cholesterol levels in the individuals who were on protease inhibitors. It was also observed that the HDL cholesterol levels decreased with an increase in the duration of the therapy. The LDL cholesterol levels increased with the duration of the therapy.
CONCLUSION: The human immunodeficiency virus infection is itself related to the metabolic complications which are aggravated on the use of second line anti retroviral therapy. Therefore, after initiating the treatment with protease inhibitors, a periodic evaluation of the serum lipid levels and the blood sugar profile should be done as a standard care.

Entities:  

Keywords:  ART; Dyslipidaemia; HAART; HIV; Metabolic syndrome

Year:  2013        PMID: 23542168      PMCID: PMC3592289          DOI: 10.7860/JCDR/2013/4740.2743

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

1.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.

Authors:  D Périard; A Telenti; P Sudre; J J Cheseaux; P Halfon; M J Reymond; S M Marcovina; M P Glauser; P Nicod; R Darioli; V Mooser
Journal:  Circulation       Date:  1999-08-17       Impact factor: 29.690

2.  Metabolic complications of protease inhibitors: what have we learned so far?

Authors:  E J Erbelding
Journal:  Hopkins HIV Rep       Date:  1999-03

Review 3.  Metabolic effects of protease inhibitor therapy.

Authors:  E Bernasconi
Journal:  AIDS Read       Date:  1999-07

Review 4.  Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.

Authors:  David C Rhew; Myriam Bernal; Daniel Aguilar; Uchenna Iloeje; Matthew Bidwell Goetz
Journal:  Clin Infect Dis       Date:  2003-09-12       Impact factor: 9.079

5.  Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.

Authors:  Katherine Samaras; Handan Wand; Matthew Law; Sean Emery; David Cooper; Andrew Carr
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

Review 6.  Dyslipidemia related to antiretroviral therapy.

Authors:  Vicente Estrada; Joaquín Portilla
Journal:  AIDS Rev       Date:  2011 Jan-Mar       Impact factor: 2.500

7.  [Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients].

Authors:  Javier Ena; Concepción Benito; Pau Llácer; Francisco Pasquau; Concepción Amador
Journal:  Med Clin (Barc)       Date:  2004-05-22       Impact factor: 1.725

Review 8.  [Metabolic side effects of antiretroviral therapy].

Authors:  M van der Valk; P Reiss
Journal:  Ned Tijdschr Geneeskd       Date:  2008-05-31

9.  Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.

Authors:  Narin Hiransuthikul; Pornthip Hiransuthikul; Yootana Kanasook
Journal:  Southeast Asian J Trop Med Public Health       Date:  2007-01       Impact factor: 0.267

Review 10.  Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Authors:  Leonardo Calza; Roberto Manfredi; Francesco Chiodo
Journal:  J Antimicrob Chemother       Date:  2003-11-25       Impact factor: 5.790

  10 in total
  1 in total

1.  Metabolic abnormalities in human immunodeficiency virus patients with protease inhibitor-based therapy.

Authors:  Tumnyak Ete; Salam Ranabir; Narmada Thongam; Biplab Ningthoujam; Narendra Rajkumar; Bhimo Thongam
Journal:  Indian J Sex Transm Dis AIDS       Date:  2014 Jul-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.